Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arthur Y Kim

Showing results (81-90 of 193) with videos related to

Pageof 20
Sort By:
Current HIV/AIDS Reports|November 8, 2025
Envisioning a Multidisciplinary HBV Cure Research AgendaKarine Dubé, Ali Ahmed, Chari Cohen, et al.
Annals of Internal Medicine|December 12, 2022
Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort StudyScott Dryden-Peterson, Andy Kim, Arthur Y Kim, et al.
AIDS (London, England)|March 28, 2014
The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patientsBenjamin P Linas, Devra M Barter, Jared A Leff, et al.
Journal of Hepatology|April 17, 2017
HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugsChristine Thöns, Tina Senff, Theresa J Hydes, et al.
Antiviral Therapy|October 7, 2015
The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular diseaseTracey G Simon, Arthur Y Kim, Luisa M Stamm, et al.
Open Forum Infectious Diseases|May 9, 2017
Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1Benjamin P Linas, Jake R Morgan, Mai T Pho, et al.
The Journal of Infectious Diseases|August 22, 2013
Variants in HAVCR1 gene region contribute to hepatitis C persistence in African AmericansGenevieve Wojcik, Rachel Latanich, Tim Mosbruger, et al.
Contemporary Clinical Trials|November 1, 2019
Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO studyAlain H Litwin, John Jost, Katherine Wagner, et al.
Infection Control and Hospital Epidemiology|September 12, 2009
Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workersKathleen E Corey, Julie C Servoss, Deborah R Casson, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 9, 2017
Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKDMeghan E Sise, Elke Backman, Guillermo A Ortiz, et al.
Pageof 20

Showing results (81-90 of 193) with videos related to

Sort By:
Pageof 20
Current HIV/AIDS Reports|November 8, 2025
Envisioning a Multidisciplinary HBV Cure Research AgendaKarine Dubé, Ali Ahmed, Chari Cohen, et al.
Annals of Internal Medicine|December 12, 2022
Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort StudyScott Dryden-Peterson, Andy Kim, Arthur Y Kim, et al.
AIDS (London, England)|March 28, 2014
The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patientsBenjamin P Linas, Devra M Barter, Jared A Leff, et al.
Journal of Hepatology|April 17, 2017
HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugsChristine Thöns, Tina Senff, Theresa J Hydes, et al.
Antiviral Therapy|October 7, 2015
The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular diseaseTracey G Simon, Arthur Y Kim, Luisa M Stamm, et al.
Open Forum Infectious Diseases|May 9, 2017
Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1Benjamin P Linas, Jake R Morgan, Mai T Pho, et al.
The Journal of Infectious Diseases|August 22, 2013
Variants in HAVCR1 gene region contribute to hepatitis C persistence in African AmericansGenevieve Wojcik, Rachel Latanich, Tim Mosbruger, et al.
Contemporary Clinical Trials|November 1, 2019
Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO studyAlain H Litwin, John Jost, Katherine Wagner, et al.
Infection Control and Hospital Epidemiology|September 12, 2009
Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workersKathleen E Corey, Julie C Servoss, Deborah R Casson, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 9, 2017
Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKDMeghan E Sise, Elke Backman, Guillermo A Ortiz, et al.
Pageof 20